In conclusion, our meta-analysis indicated that the expression of TUBB3 may be a useful biomarker to predict the clinical outcomes of taxane/vinorebine-based chemotherapy in patients with NSCLC. This evidence concerns the gene TUBB3 and non-small cell lung carcinoma.